Journal: Clin Cancer Res
Publication Date: 2025-11-03
DOI: 10.1158/1078-0432.CCR-25-2013
NIH Citation: Aggen DH, McKean M, Hoffman-Censits JH, Lakhani NJ, Alhalabi O, Guancial EA, Bashir B, Bowman IA, Tan A, Lingaraj T, Ortiz-Otero N, Bartolini W, Timothy M, Kim K, Kacena K, Santillana SS, Luke JJ. IK-175, an oral aryl hydrocarbon receptor inhibitor, alone and with nivolumab in patients with advanced solid tumors and urothelial carcinoma. Clin Cancer Res. 2025;.
PubMed PMID: 41182348
Journal: Cancer Discov
Publication Date: 2025-11-03
DOI: 10.1158/2159-8290.CD-25-0247
NIH Citation: Morder KM, Nguyen M, Wilfahrt DN, Dahmani ZL, Burr AB, Xie B, Morikone M, Nieves-Rosado H, Gunn WG, Hurd DE, Wang H, Mullett SJ, Bossong K, Gelhaus SL, Rajasundaram D, Kane LP, Delgoffe GM, Das J, Davar D, Overacre-Delgoffe AE. Sucralose consumption ablates cancer immunotherapy response through microbiome disruption. Cancer Discov. 2025;. PMCID: PMC12580791.
PubMed PMID: 40742298
Journal: Nat Rev Clin Oncol
Publication Date: 2025-11-01
DOI: 10.1038/s41571-025-01065-3
NIH Citation: Cillo AR, Kirkwood JM. Surprising role of CMV in shaping outcomes of immunotherapy for melanoma - chronic infection yields favourable survival. Nat Rev Clin Oncol. 2025;.
PubMed PMID: 40764412
Journal: Nat Rev Chem
Publication Date: 2025-10-29
DOI: 10.1038/s41570-025-00768-6
NIH Citation: Adams EL, McGovern AC, So V, Srinivasan S, Deiters A, Lohmueller J. Small-molecule control of CAR T cells. Nat Rev Chem. 2025;.
PubMed PMID: 41162648
Journal: Immunity
Publication Date: 2025-10-14
DOI: 10.1016/j.immuni.2025.06.018
NIH Citation: Pandey SP, Yang D, Hedden L, Laughlin CR, Wang W, Soto AS, Winner H, Medina Sanchez L, Campana EE, Engl C, Zeng Y, Rana M, Van Der Kraak L, Bender MJ, Prokopec J, Ferrick JM, Meng X, Fong E, Sun M, Mullett SJ, MacDonald M, Gelhaus SL, Watkins SC, Meisel M, von Moltke J, Xu S, Gong YN, Hinterleitner R. Gasdermin C cleavage by Cathepsin S modulates Rab7 vesicles in intestinal epithelial cells to amplify anti-helminth immunity. Immunity. 2025;. PMCID: PMC12380176.
PubMed PMID: 40701157
Journal: Immunity
Publication Date: 2025-10-14
DOI: 10.1016/j.immuni.2025.08.008
NIH Citation: Rivadeneira DB, Thosar S, Quann K, Gunn WG, Dean VG, Xie B, Parise A, McGovern AC, Spahr K, Lontos K, Barnes RP, Bruchez MP, Opresko PL, Delgoffe GM. Oxidative-stress-induced telomere instability drives T cell dysfunction in cancer. Immunity. 2025;.
PubMed PMID: 40930086
Journal: Cell
Publication Date: 2025-10-02
DOI: 10.1016/j.cell.2025.06.018
NIH Citation: Phelps CM, Willis NB, Duan T, Lee AH, Zhang Y, Rodriguez J DM, Pandey SP, Laughlin CR, Rosen ABI, McPherson AC, Shapira JH, Randhawa SK, Hedden L, Richie TG, Wiechman HM, Bender MJ, Nemet I, Zöhrer PA, Gottschalk RA, Schmitz KH, Mullett SJ, Gelhaus SL, Davar D, Zarour HM, Hinterleitner R, Mossington T, Badger JH, Rodrigues RR, McCulloch JA, Lee STM, Wagner KH, Winter MG, Winter SE, Das J, Pierre JF, Trinchieri G, Meisel M. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell. 2025;. PMCID: PMC12258965.
PubMed PMID: 40639377
Journal: Nat Commun
Publication Date: 2025-09-29
DOI: 10.1038/s41467-025-63579-9
NIH Citation: Park JC, Curti B, Butler M, Wehrenberg-Klee E, Elassal J, Tighe R, Battula S, Iodice G, Kaufman HL, Kirkwood JM. Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial. Nat Commun. 2025;16(1):8567. PMCID: PMC12480005.
PubMed PMID: 41022754
Journal: Nat Rev Cancer
Publication Date: 2025-09-01
DOI: 10.1038/s41568-025-00832-9
NIH Citation: Imianowski CJ, Chen Q, Workman CJ, Vignali DAA. Regulatory T cells in the tumour microenvironment. Nat Rev Cancer. 2025;.
PubMed PMID: 40494998
Journal: JAMA
Publication Date: 2025-08-25
DOI: 10.1001/jama.2025.13074
NIH Citation: Joshi UM, Kashani-Sabet M, Kirkwood JM. Cutaneous Melanoma: A Review. JAMA. 2025;.
PubMed PMID: 40853557
Journal: Clin Cancer Res
Publication Date: 2025-08-14
DOI: 10.1158/1078-0432.CCR-25-1089
NIH Citation: Nguyen MK, Luke JJ. And… We're Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring. Clin Cancer Res. 2025;. PMCID: PMC12353176.
PubMed PMID: 40499143
Journal: Clin Cancer Res
Publication Date: 2025-08-14
DOI: 10.1158/1078-0432.CCR-25-0884
NIH Citation: Davar D, Eroglu Z, Pérez CL, Di Pace B, Wang T, Yanamandra N, Ghosh S, Jansen K, Dhar A, Borgovan T, Waszak A, Ribas A. Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A. Clin Cancer Res. 2025;:OF1-OF10. PMCID: PMC12351273.
PubMed PMID: 40552935
Journal: Clin Cancer Res
Publication Date: 2025-08-14
DOI: 10.1158/1078-0432.CCR-25-0806
NIH Citation: Davar D, Eroglu Z, Milhem M, Becerra C, Gutierrez M, Ribas A, Di Pace B, Wang T, Zhang H, Ghosh S, Yanamandra N, Borgovan T, Srivats S, Waszak A, Dhar A, LoRusso P. Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B. Clin Cancer Res. 2025;:OF1-OF9. PMCID: PMC12351275.
PubMed PMID: 40552922
Journal: J Exp Med
Publication Date: 2025-08-04
DOI: 10.1084/jem.20250896
NIH Citation: Kane LP. Costimulatory connections: CARMIL2 and CD28. J Exp Med. 2025;222(8). PMCID: PMC12187082.
PubMed PMID: 40540742
Journal: Clin Cancer Res
Publication Date: 2025-08-01
DOI: 10.1158/1078-0432.CCR-24-3980
NIH Citation: Tarhini AA, Obermayer A, Lee SJ, LaFramboise WA, Hodi FS, Karunamurthy AD, Eljilany I, Chen DT, Hwu P, El Naqa IM, Streicher H, Sondak VK, Storkus WJ, Butterfield LH, Shaw TI, Kirkwood JM. Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk Melanoma. Clin Cancer Res. 2025;. PMCID: PMC12316551.
PubMed PMID: 40392969
Journal: Clin Cancer Res
Publication Date: 2025-07-15
DOI: 10.1158/1078-0432.CCR-25-0654
NIH Citation: Patel RB, Adler SS, Escorcia FE. Size matters: Superior Efficacy of Alpha Particle Radioimmunotherapy in Micrometastases versus Macrometastases. Clin Cancer Res. 2025;.
PubMed PMID: 40366383
Journal: J Immunother Cancer
Publication Date: 2025-07-08
DOI: 10.1136/jitc-2025-011652
NIH Citation: Davar D, Anderson AC, Diaz-Padilla I. Therapeutic potential of targeting LAG-3 in cancer. J Immunother Cancer. 2025;13(7). PMCID: PMC12243602.
PubMed PMID: 40633935
Journal: J Immunother Cancer
Publication Date: 2025-06-19
DOI: 10.1136/jitc-2024-011453
NIH Citation: Carleton N, Lotze MT. Reciprocal immune-epithelial interaction during breast cancer induction. J Immunother Cancer. 2025;13(6). PMCID: PMC12182196.
PubMed PMID: 40537241
Journal: Clin Cancer Res
Publication Date: 2025-06-03
DOI: 10.1158/1078-0432.CCR-24-0439
NIH Citation: Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, Carlino MS, Pachynski RK, Cosman R, Chu QS, Damian S, Curigliano G, Tam R, Wang X, Jeyamohan C, Wang L, Zhu L, Santucci-Pereira J, Greenawalt DM, Tabernero J. Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. Clin Cancer Res. 2025;.
PubMed PMID: 39670852
Journal: J Immunother Cancer
Publication Date: 2025-05-19
DOI: 10.1136/jitc-2024-011170
NIH Citation: Luke JJ, Bever K, Hodi FS, Taube J, Massey A, Yao D, Neely J, Tam R, Lee G, Gupta A, Dutta S, Szabo P, Bao R, Reilly T. Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial. J Immunother Cancer. 2025;13(5). PMCID: PMC12090868.
PubMed PMID: 40389374
Journal: Mol Ther
Publication Date: 2025-05-07
DOI: 10.1016/j.ymthe.2025.03.042
NIH Citation: Carleton N, Rosen ABI, Das J, Lotze MT. Immuno-oncology recapitulates ontogeny: Modern cell and gene therapy for cancer. Mol Ther. 2025;. PMCID: PMC12126835.
PubMed PMID: 40156188
Journal: Nat Cell Biol
Publication Date: 2025-05-01
DOI: 10.1038/s41556-025-01650-9
NIH Citation: Wang Y, Wilfahrt D, Jonker P, Lontos K, Cai C, Cameron B, Xie B, Peralta RM, Schoedel ER, Gunn WG, AminiTabrizi R, Shah H, Rivadeneira DB, Muir A, Delgoffe GM. Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function. Nat Cell Biol. 2025;.
PubMed PMID: 40258951
Journal: Cancer Cell
Publication Date: 2025-04-14
DOI: 10.1016/j.ccell.2025.02.026
NIH Citation: Li H, Zandberg DP, Kulkarni A, Chiosea SI, Santos PM, Isett BR, Joy M, Sica GL, Contrera KJ, Tatsuoka CM, Brand M, Duvvuri U, Kim S, Kubik M, Sridharan S, Tu F, Chen J, Bruno TC, Vignali DAA, Cillo AR, Bao R, Wang JH, Vujanovic L, Ferris RL. Distinct CD8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell. 2025;. PMCID: PMC12359303.
PubMed PMID: 40086437
Journal: Clin Cancer Res
Publication Date: 2025-04-01
DOI: 10.1158/1078-0432.CCR-24-2824
NIH Citation: Luke JJ, Sweis RF, Hecht JR, Schneider R, Stein MN, Golan T, Yap TA, Khilnani A, Huang M, Zhao R, Jemielita T, Patel SP. Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025;. PMCID: PMC11964177.
PubMed PMID: 39846804
Journal: Cell Metab
Publication Date: 2025-04-01
DOI: 10.1016/j.cmet.2024.12.007
NIH Citation: Frisch AT, Wang Y, Xie B, Yang A, Ford BR, Joshi S, Kedziora KM, Peralta R, Wilfahrt D, Mullett SJ, Spahr K, Lontos K, Jana JA, Dean VG, Gunn WG, Gelhaus S, Poholek AC, Rivadeneira DB, Delgoffe GM. Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy. Cell Metab. 2025;. PMCID: PMC12101091.
PubMed PMID: 39879981
Journal: Sci Transl Med
Publication Date: 2025-03-19
DOI: 10.1126/scitranslmed.adp0675
NIH Citation: Raphael I, Xiong Z, Sneiderman CT, Raphael RA, Mash M, Schwegman L, Jackson SA, O'Brien C, Anderson KJ, Sever RE, Hendrikse LD, Vincze SR, Diaz A, Felker J, Nazarian J, Nechemia-Arbely Y, Hu B, Kammula US, Agnihotri S, Rich JN, Broniscer A, Drappatz J, Abel TJ, Uttam S, Hwang EI, Pearce TM, Taylor MD, Nisnboym M, Forsthuber TG, Pollack IF, Chikina M, Rajasundaram D, Kohanbash G. The T cell receptor landscape of childhood brain tumors. Sci Transl Med. 2025;17(790):eadp0675. PMCID: PMC12360399.
PubMed PMID: 40106578
Journal: J Immunother Cancer
Publication Date: 2025-03-18
DOI: 10.1136/jitc-2025-011581
NIH Citation: Kohanbash G, Frederico SC, Raphael I. NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases. J Immunother Cancer. 2025;13(3). PMCID: PMC11927483.
PubMed PMID: 40107674
Journal: J Control Release
Publication Date: 2025-03-10
DOI: 10.1016/j.jconrel.2025.01.011
NIH Citation: Li J, Patel SK, Sweeney Y, Patton D, Anderson P, Hillier SL, Rohan LC. Engineering vaginal film platform for mucoadhesion and sustained drug release for HIV-1 prevention. J Control Release. 2025;.
PubMed PMID: 39814320
Journal: J Immunother Cancer
Publication Date: 2025-02-20
DOI: 10.1136/jitc-2024-010511
NIH Citation: Luke JJ, Pinato DJ, Juric D, LoRusso P, Hosein PJ, Desai AM, Haddad R, de Miguel M, Cervantes A, Kim WS, Marabelle A, Zhang Y, Rong Y, Yuan X, Champiat S. Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors. J Immunother Cancer. 2025;13(2). PMCID: PMC11842995.
PubMed PMID: 39979069
Journal: Sci Transl Med
Publication Date: 2025-02-19
DOI: 10.1126/scitranslmed.adh1315
NIH Citation: Ruffin AT, Casey AN, Kunning SR, MacFawn IP, Liu Z, Arora C, Rohatgi A, Kemp F, Lampenfeld C, Somasundaram A, Rappocciolo G, Kirkwood JM, Duvvuri U, Seethala R, Bao R, Huang Y, Cillo AR, Ferris RL, Bruno TC. Dysfunctional CD11c(-)CD21(-) extrafollicular memory B cells are enriched in the periphery and tumors of patients with cancer. Sci Transl Med. 2025;17(786):eadh1315. PMCID: PMC12183695.
PubMed PMID: 39970232
Journal: J Am Chem Soc
Publication Date: 2025-01-29
DOI: 10.1021/jacs.4c13870
NIH Citation: Kuwik J, Scott V, Chedid S, Stransky S, Hinkelman K, Kavoosi S, Calderon M, Watkins S, Sidoli S, Islam K. Analogue-Sensitive Inhibition of Histone Demethylases Uncovers Member-Specific Function in Ribosomal Protein Synthesis. J Am Chem Soc. 2025;. PMCID: PMC11783601.
PubMed PMID: 39808475
Journal: J Immunother Cancer
Publication Date: 2025-01-23
DOI: 10.1136/jitc-2024-010376
NIH Citation: Whiteside TL. Biology of extracellular vesicles and the potential of tumor-derived vesicles for subverting immunotherapy of cancer. J Immunother Cancer. 2025;13(1). PMCID: PMC11759217.
PubMed PMID: 39855711
Journal: Trends Cancer
Publication Date: 2025-01-01
DOI: 10.1016/j.trecan.2024.10.009
NIH Citation: Adam K, Butler SC, Workman CJ, Vignali DAA. Advances in LAG3 cancer immunotherapeutics. Trends Cancer. 2025;. PMCID: PMC12047404.
PubMed PMID: 39603977
Journal: Nat Rev Immunol
Publication Date: 2024-12-01
DOI: 10.1038/s41577-024-01061-1
NIH Citation: Lotze MT, Olejniczak SH, Skokos D. CD28 co-stimulation: novel insights and applications in cancer immunotherapy. Nat Rev Immunol. 2024;. PMCID: PMC11598642.
PubMed PMID: 39054343
Journal: Nat Immunol
Publication Date: 2024-12-01
DOI: 10.1038/s41590-024-01999-3
NIH Citation: Peralta RM, Xie B, Lontos K, Nieves-Rosado H, Spahr K, Joshi S, Ford BR, Quann K, Frisch AT, Dean V, Philbin M, Cillo AR, Gingras S, Poholek AC, Kane LP, Rivadeneira DB, Delgoffe GM. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat Immunol. 2024;. PMCID: PMC11588660.
PubMed PMID: 39516648
Journal: J Immunother Cancer
Publication Date: 2024-11-17
DOI: 10.1136/jitc-2024-009336
NIH Citation: Davar D, Carneiro BA, Dy GK, Sheth S, Borad MJ, Harrington KJ, Patel SP, Galanis E, Samson A, Agrawal S, Chen Z, Fan C, Gong M, Burton J, Tu E, Durham N, Laubscher K, Arnaldez F, Zamarin D. Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. J Immunother Cancer. 2024;12(11). PMCID: PMC11574399.
PubMed PMID: 39551600
Journal: J Immunother Cancer
Publication Date: 2024-11-12
DOI: 10.1136/jitc-2024-009231
NIH Citation: Karapetyan L, Li A, Vargas De Stefano D, Abushukair HM, Al-Bzour AN, Knight A, Layding C, Wang H, Xu J, Yao J, Song X, Joy M, Nguyen J, Moran-Segura C, Bruno S, Sander C, Messina J, Mule JJ, Storkus WJ, Kirkwood JM. Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas. J Immunother Cancer. 2024;12(11). PMCID: PMC11575263.
PubMed PMID: 39537211
Journal: Cancer Cell
Publication Date: 2024-11-11
DOI: 10.1016/j.ccell.2024.10.007
NIH Citation: Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, Deutsch JS, Das Neves RX, Rodrigues RR, McCulloch JA, Wang H, Hartman DJ, Badger JH, Fernandes MR, Bai Y, Sun J, Cole AM, Aggarwal P, Fang JR, Deitrick C, Bao R, Duvvuri U, Sridharan SS, Kim SW, A Choudry H, Holtzman MP, Pingpank JF, O'Toole JP, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg AM, Fury MG, Whiteaker JR, Zhao L, Paulovich AG, Najjar YG, Luke JJ, Kirkwood JM, Taube JM, Park HJ, Trinchieri G, Zarour HM. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024;42(11):1898-1918.e12. PMCID: PMC11560503.
PubMed PMID: 39486411
Journal: Cancer Cell
Publication Date: 2024-11-11
DOI: 10.1016/j.ccell.2024.09.007
NIH Citation: MacFawn IP, Magnon G, Gorecki G, Kunning S, Rashid R, Kaiza ME, Atiya H, Ruffin AT, Taylor S, Soong TR, Bao R, Coffman LG, Bruno TC. The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions. Cancer Cell. 2024;. PMCID: PMC12236807.
PubMed PMID: 39393357
Journal: J Clin Invest
Publication Date: 2024-11-01
DOI: 10.1172/JCI175147
NIH Citation: Hamze Sinno S, Imperatore JA, Bai S, Gomes-Jourdan N, Mafarachisi N, Coronnello C, Zhang L, Jašarević E, Osmanbeyoglu HU, Buckanovich RJ, Cascio S. Egfl6 promotes ovarian cancer progression by enhancing the immunosuppressive functions of tumor-associated myeloid cells. J Clin Invest. 2024;. PMCID: PMC11527450.
PubMed PMID: 39312740
Journal: Clin Cancer Res
Publication Date: 2024-09-13
DOI: 10.1158/1078-0432.CCR-24-1363
NIH Citation: Mowery YM, Luke JJ. NETosis Impact on Tumor Biology, Radiation, and Systemic Therapy Resistance. Clin Cancer Res. 2024;. PMCID: PMC11398986.
PubMed PMID: 39007757
Journal: J Immunother Cancer
Publication Date: 2024-09-10
DOI: 10.1136/jitc-2024-010464
NIH Citation: Luke JJ, Hamid O, Fox BA, Ascierto PA, Osman I, Mule JJ, Romero PJ, Lotze MT. Jeffrey S Weber, MD, PhD (1952-2024): in memoriam to discovery, friendship and family. J Immunother Cancer. 2024;12(9).
PubMed PMID: 39260827
Journal: Cancer Cell
Publication Date: 2024-09-09
DOI: 10.1016/j.ccell.2024.08.014
NIH Citation: Cillo AR, Kirkwood JM. Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone. Cancer Cell. 2024;42(9):1491-1493.
PubMed PMID: 39255774
Journal: J Immunother Cancer
Publication Date: 2024-08-17
DOI: 10.1136/jitc-2024-009062
NIH Citation: DePeaux K, Gunn WG, Rivadeneira DB, Delgoffe GM. Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells. J Immunother Cancer. 2024;12(8). PMCID: PMC11331848.
PubMed PMID: 39153823
Journal: J Immunother Cancer
Publication Date: 2024-08-13
DOI: 10.1136/jitc-2024-009475
NIH Citation: Cavalcante L, Chandana S, Lakhani N, Enstrom A, LeBlanc H, Schmalz J, Lengyel K, Schneider F, Thomas H, Chisamore MJ, Peng SL, Naumovski A, Davar D. Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. J Immunother Cancer. 2024;12(8). PMCID: PMC11337706.
PubMed PMID: 39142718
Journal: Cell
Publication Date: 2024-08-08
DOI: 10.1016/j.cell.2024.06.036
NIH Citation: Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, Rush E, Karunamurthy A, Massa RC, Rohatgi A, Workman CJ, Kirkwood JM, Bruno TC, Vignali DAA. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity. Cell. 2024;187(16):4373-4388.e15. PMCID: PMC11346583.
PubMed PMID: 39121849
Journal: Cell
Publication Date: 2024-08-08
DOI: 10.1016/j.cell.2024.07.016
NIH Citation: Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, Liu C, Brunazzi EA, Baessler A, Xie B, Kunning SR, Ngiow SF, Huang YJ, Manne S, Sharpe AH, Delgoffe GM, Wherry EJ, Kirkwood JM, Bruno TC, Workman CJ, Vignali DAA. LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity. Cell. 2024;187(16):4355-4372.e22. PMCID: PMC11323044.
PubMed PMID: 39121848
Journal: J Immunother Cancer
Publication Date: 2024-08-03
DOI: 10.1136/jitc-2024-009474
NIH Citation: Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, Voskoboynik M, Sanborn RE, Grewal JS, Narayan A, Patnaik A, Gainor JF, Sznol M, Enstrom A, Blanchfield L, LeBlanc H, Thomas H, Chisamore MJ, Peng SL, Naumovski A. Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). J Immunother Cancer. 2024;12(8). PMCID: PMC11344531.
PubMed PMID: 39097413
Journal: Cancer Discov
Publication Date: 2024-08-02
DOI: 10.1158/2159-8290.CD-24-0645
NIH Citation: Lotze MT, Maeurer M, Quezada SA, Coukos G. Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage. Cancer Discov. 2024;14(8):1366-1368.
PubMed PMID: 39091204
Journal: Cancer Res
Publication Date: 2024-08-01
DOI: 10.1158/0008-5472.CAN-24-1833
NIH Citation: Lee AH, Randhawa SK, Meisel M. Dietary commensal wrestles iron from tumor microenvironment to activate antitumoral macrophages. Cancer Res. 2024;. PMCID: PMC11552448.
PubMed PMID: 38832925
Journal: J Immunother Cancer
Publication Date: 2024-07-22
DOI: 10.1136/jitc-2024-008837
NIH Citation: Ghosh CC, Cournoyer L, Liu Y, Ballarin A, Layman IB, LaPorte J, Morrissey M, Fraser K, Perati S, Cox BF, Yakirevich E, Treaba DO, Murtha TD, Guha P, Katz SC, Davar D. Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases. J Immunother Cancer. 2024;12(7). PMCID: PMC11268044.
PubMed PMID: 39038918
Journal: J Immunother Cancer
Publication Date: 2024-06-19
DOI: 10.1136/jitc-2024-009661
NIH Citation: van der Burg SH, Lotze MT. Perspectives from the leadership of Journal for ImmunoTherapy of Cancer. J Immunother Cancer. 2024;12(6). PMCID: PMC11191768.
PubMed PMID: 38901880
Journal: Nat Rev Clin Oncol
Publication Date: 2024-06-01
DOI: 10.1038/s41571-024-00882-2
NIH Citation: Maleki Vareki S, Davar D. Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges. Nat Rev Clin Oncol. 2024;.
PubMed PMID: 38509333
Journal: Nat Rev Immunol
Publication Date: 2024-06-01
DOI: 10.1038/s41577-023-00973-8
NIH Citation: Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;. PMCID: PMC11460566.
PubMed PMID: 38057451
Journal: Annu Rev Immunol
Publication Date: 2024-06-01
DOI: 10.1146/annurev-immunol-090222-110914
NIH Citation: Baessler A, Vignali DAA. T Cell Exhaustion. Annu Rev Immunol. 2024;.
PubMed PMID: 38166256
Journal: J Clin Oncol
Publication Date: 2024-05-10
DOI: 10.1200/JCO.23.02355
NIH Citation: Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024;:JCO2302355. PMCID: PMC11095869.
PubMed PMID: 38452313
Journal: JAMA Oncol
Publication Date: 2024-05-01
DOI: 10.1001/jamaoncol.2023.7333
NIH Citation: Mangla A, Lee C, Mirsky MM, Wang M, Rothermel LD, Hoehn R, Bordeaux JS, Carrol BT, Theuner J, Li S, Fu P, Kirkwood JM. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 2024;. PMCID: PMC10979364.
PubMed PMID: 38546551
Journal: Clin Cancer Res
Publication Date: 2024-05-01
DOI: 10.1158/1078-0432.CCR-23-3736
NIH Citation: Vignali PDA, Luke JJ. Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clin Cancer Res. 2024;. PMCID: PMC11062819.
PubMed PMID: 38372597
Journal: J Immunother Cancer
Publication Date: 2024-04-18
DOI: 10.1136/jitc-2023-008378
NIH Citation: Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. J Immunother Cancer. 2024;12(4). PMCID: PMC11029323.
PubMed PMID: 38641350
Journal: Nat Commun
Publication Date: 2024-04-16
DOI: 10.1038/s41467-024-46906-4
NIH Citation: Leonard-Murali S, Bhaskarla C, Yadav GS, Maurya SK, Galiveti CR, Tobin JA, Kann RJ, Ashwat E, Murphy PS, Chakka AB, Soman V, Cantalupo PG, Zhuo X, Vyas G, Kozak DL, Kelly LM, Smith E, Chandran UR, Hsu YS, Kammula US. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility. Nat Commun. 2024;15(1):2863. PMCID: PMC11021475.
PubMed PMID: 38627362
Journal: J Immunother Cancer
Publication Date: 2024-03-21
DOI: 10.1136/jitc-2023-008655
NIH Citation: Sitc S, Lotze MT, Cottrell T, Bifulco C, Chow L, Cope L, Gnjatic S, Maecker HT, Yeong Poh Shen J. SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials. J Immunother Cancer. 2024;12(3). PMCID: PMC10961490.
PubMed PMID: 38519056
Journal: EBioMedicine
Publication Date: 2024-02-01
DOI: 10.1016/j.ebiom.2023.104963
NIH Citation: Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G. Glioblastoma vaccines: past, present, and opportunities. EBioMedicine. 2024;100:104963. PMCID: PMC10808938.
PubMed PMID: 38183840
Journal: Trends Cancer
Publication Date: 2024-02-01
DOI: 10.1016/j.trecan.2023.09.012
NIH Citation: DePeaux K, Delgoffe GM. Integrating innate and adaptive immunity in oncolytic virus therapy. Trends Cancer. 2024;. PMCID: PMC10922271.
PubMed PMID: 37880008
Journal: Nat Immunol
Publication Date: 2024-02-01
DOI: 10.1038/s41590-023-01733-5
NIH Citation: Wilfahrt D, Delgoffe GM. Metabolic waypoints during T cell differentiation. Nat Immunol. 2024;.
PubMed PMID: 38238609
Journal: Clin Cancer Res
Publication Date: 2024-01-17
DOI: 10.1158/1078-0432.CCR-23-3320
NIH Citation: Silk AW, Davar D. Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024;:OF1-OF3.
PubMed PMID: 38230965
Journal: Immunity
Publication Date: 2024-01-09
DOI: 10.1016/j.immuni.2023.12.011
NIH Citation: Jana JA, Overacre-Delgoffe AE. You are the tumor queen, microbiome fiend, IL-17. Immunity. 2024;57(1):11-13.
PubMed PMID: 38198848
Journal: Clin Cancer Res
Publication Date: 2024-01-05
DOI: 10.1158/1078-0432.CCR-23-2437
NIH Citation: Wu RC, Luke JJ. Uncovering the potential of CD40 agonism to enhance immune-checkpoint blockade. Clin Cancer Res. 2024;. PMCID: PMC10842335.
PubMed PMID: 37870487
Journal: Clin Cancer Res
Publication Date: 2024-01-03
DOI: 10.1158/1078-0432.CCR-23-3320
NIH Citation: Silk AW, Davar D. Tumor-associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024;.
PubMed PMID: 38170200
Journal: Nat Rev Immunol
Publication Date: 2023-12-01
DOI: 10.1038/s41577-023-00894-6
NIH Citation: Tang D, Kang R, Zeh HJ, Lotze MT. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol. 2023;.
PubMed PMID: 37322174
Journal: Nat Med
Publication Date: 2023-11-01
DOI: 10.1038/s41591-023-02583-2
NIH Citation: Kirkwood J, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023;. PMCID: PMC10667090.
PubMed PMID: 37845511
Journal: Nat Med
Publication Date: 2023-11-01
DOI: 10.1038/s41591-023-02593-0
NIH Citation: Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023;. PMCID: PMC10667103.
PubMed PMID: 37857711
Journal: J Exp Med
Publication Date: 2023-10-02
DOI: 10.1084/jem.20230053
NIH Citation: DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, Yao T, Wilfahrt D, Hinck C, Wieteska L, Thorne SH, Hinck AP, Delgoffe GM. An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment. J Exp Med. 2023;220(10). PMCID: PMC10407786.
PubMed PMID: 37552475
Journal: Clin Cancer Res
Publication Date: 2023-10-02
DOI: 10.1158/1078-0432.CCR-23-1333
NIH Citation: Betof Warner A, Luke JJ. CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II. Clin Cancer Res. 2023;. PMCID: PMC10592266.
PubMed PMID: 37534980
Journal: J Am Chem Soc
Publication Date: 2023-09-27
DOI: 10.1021/jacs.3c07299
NIH Citation: Kuwik J, Hinkelman K, Waldman M, Stepler KE, Wagner S, Arora S, Chernenkoff S, Cabalteja C, Sidoli S, Robinson RA, Islam K. Activity Guided Azide-methyllysine Photo-trapping for Substrate Profiling of Lysine Demethylases. J Am Chem Soc. 2023;. PMCID: PMC10540216.
PubMed PMID: 37703462
Journal: Sci Immunol
Publication Date: 2023-09-15
DOI: 10.1126/sciimmunol.adf6717
NIH Citation: Shan F, Cillo AR, Cardello C, Yuan DY, Kunning SR, Cui J, Lampenfeld C, Williams AM, McDonough AP, Pennathur A, Luketich JD, Kirkwood JM, Ferris RL, Bruno TC, Workman CJ, Benos PV, Vignali DAA. Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells. Sci Immunol. 2023;8(87):eadf6717. PMCID: PMC11045170.
PubMed PMID: 37713508
Journal: J Clin Oncol
Publication Date: 2023-09-10
DOI: 10.1200/JCO.23.00255
NIH Citation: Zhang X, Ferris L, Faries MB, Luke JJ. Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era. J Clin Oncol. 2023;:JCO2300255. PMCID: PMC10852382.
PubMed PMID: 37410978
Journal: Nat Immunol
Publication Date: 2023-09-01
DOI: 10.1038/s41590-023-01569-z
NIH Citation: Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415-1422. PMCID: PMC11144386.
PubMed PMID: 37488429
Journal: Clin Cancer Res
Publication Date: 2023-09-01
DOI: 10.1158/1078-0432.CCR-23-1194
NIH Citation: Augustin RC, Luke JJ. PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long? Clin Cancer Res. 2023;29(17):3253-3255. PMCID: PMC10527539.
PubMed PMID: 37378689
Journal: Immunity
Publication Date: 2023-08-08
DOI: 10.1016/j.immuni.2023.06.022
NIH Citation: Medina Sanchez L, Siller M, Zeng Y, Brigleb PH, Sangani KA, Soto AS, Engl C, Laughlin CR, Rana M, Van Der Kraak L, Pandey SP, Bender MJ, Fitzgerald B, Hedden L, Fiske K, Taylor GM, Wright AP, Mehta ID, Rahman SA, Galipeau HJ, Mullett SJ, Gelhaus SL, Watkins SC, Bercik P, Nice TJ, Jabri B, Meisel M, Das J, Dermody TS, Verdú EF, Hinterleitner R. The gut protist Tritrichomonas arnold restrains virus-mediated loss of oral tolerance by modulating dietary antigen-presenting dendritic cells. Immunity. 2023;56(8):1862-1875.e9. PMCID: PMC10529081.
PubMed PMID: 37478853
Journal: Clin Cancer Res
Publication Date: 2023-07-05
DOI: 10.1158/1078-0432.CCR-23-0490
NIH Citation: Smithy JW, Luke JJ. CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade. Clin Cancer Res. 2023;29(13):2345-2347. PMCID: PMC10330271.
PubMed PMID: 37097465
Journal: Clin Cancer Res
Publication Date: 2023-07-05
DOI: 10.1158/1078-0432.CCR-23-0118
NIH Citation: Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL, Janku F. Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clin Cancer Res. 2023;29(13):2435-2444. PMCID: PMC11225568.
PubMed PMID: 37227176
Journal: Trends Immunol
Publication Date: 2023-07-01
DOI: 10.1016/j.it.2023.04.007
NIH Citation: Gottschalk RA. Signaling is the pathway to macrophage function. Trends Immunol. 2023;44(7):496-498. PMCID: PMC11460561.
PubMed PMID: 37258361
Journal: Lancet Digit Health
Publication Date: 2023-06-01
DOI: 10.1016/S2589-7500(23)00046-8
NIH Citation: Kann BH, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly HR, Juliano AF, Payabvash S, Guenette JP, Uppaluri R, Margalit DN, Schoenfeld JD, Tishler RB, Haddad R, Aerts HJWL, Garcia JJ, Flamand Y, Subramaniam RM, Burtness BA, Ferris RL. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. Lancet Digit Health. 2023;5(6):e360-e369. PMCID: PMC10245380.
PubMed PMID: 37087370
Journal: J Clin Invest
Publication Date: 2023-05-15
DOI: 10.1172/JCI162260
NIH Citation: Korpics MC, Onderdonk BE, Dadey RE, Hara JH, Karapetyan L, Zha Y, Karrison TG, Olson AC, Fleming GF, Weichselbaum RR, Bao R, Chmura SJ, Luke JJ. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023;133(10). PMCID: PMC10178837.
PubMed PMID: 37183819
Journal: Clin Cancer Res
Publication Date: 2023-05-09
DOI: 10.1158/1078-0432.CCR-23-0118
NIH Citation: Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss JF, Hava DL, Janku F. Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res. 2023;.
PubMed PMID: 37159185
Journal: Nat Commun
Publication Date: 2023-05-09
DOI: 10.1038/s41467-023-37863-5
NIH Citation: Ruffo E, Butchy AA, Tivon Y, So V, Kvorjak M, Parikh A, Adams EL, Miskov-Zivanov N, Finn OJ, Deiters A, Lohmueller J. Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. Nat Commun. 2023;14(1):2463. PMCID: PMC10169838.
PubMed PMID: 37160880
Journal: JAMA Dermatol
Publication Date: 2023-05-01
DOI: 10.1001/jamadermatol.2023.0127
NIH Citation: Kashani-Sabet M, Leachman SA, Stein JA, Arbiser JL, Berry EG, Celebi JT, Curiel-Lewandrowski C, Ferris LK, Grant-Kels JM, Grossman D, Kulkarni RP, Marchetti MA, Nelson KC, Polsky D, Seiverling EV, Swetter SM, Tsao H, Verdieck-Devlaeminck A, Wei ML, Bar A, Bartlett EK, Bolognia JL, Bowles TL, Cha KB, Chu EY, Hartman RI, Hawryluk EB, Jampel RM, Karapetyan L, Kheterpal M, Lawson DH, Leming PD, Liebman TN, Ming ME, Sahni D, Savory SA, Shaikh SS, Sober AJ, Sondak VK, Spaccarelli N, Usatine RP, Venna S, Kirkwood JM. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023;159(5):545-553. PMCID: PMC11225588.
PubMed PMID: 36920356
Journal: Clin Cancer Res
Publication Date: 2023-05-01
DOI: 10.1158/1078-0432.CCR-22-3168
NIH Citation: Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, Dzubinski L, Kaufman SF, Rodriguez LM, Richmond E, Umar A, Szabo E, Salazar A, McKolanis J, Beatty P, Pai RK, Singhi AD, Jacqueline CM, Bao R, Diergaarde B, McMurray RP, Strand C, Foster NR, Zahrieh DM, Limburg PJ, Finn OJ. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma. Clin Cancer Res. 2023;29(9):1678-1688. PMCID: PMC10159922.
PubMed PMID: 36892581
Journal: Cell
Publication Date: 2023-04-27
DOI: 10.1016/j.cell.2023.03.011
NIH Citation: Bender MJ, McPherson AC, Phelps CM, Pandey SP, Laughlin CR, Shapira JH, Medina Sanchez L, Rana M, Richie TG, Mims TS, Gocher-Demske AM, Cervantes-Barragan L, Mullett SJ, Gelhaus SL, Bruno TC, Cannon N, McCulloch JA, Vignali DAA, Hinterleitner R, Joglekar AV, Pierre JF, Lee STM, Davar D, Zarour HM, Meisel M. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. 2023;186(9):1846-1862.e26. PMCID: PMC10148916.
PubMed PMID: 37028428
Journal: Clin Cancer Res
Publication Date: 2023-04-03
DOI: 10.1158/1078-0432.CCR-22-3652
NIH Citation: Olson DJ, Luke JJ. Myeloid Maturity: ATRA to Enhance Anti-PD-1? Clin Cancer Res. 2023;29(7):1167-1169. PMCID: PMC10073251.
PubMed PMID: 36656164
Journal: Nat Cancer
Publication Date: 2023-04-01
DOI: 10.1038/s43018-023-00527-w
NIH Citation: Onkar S, Cui J, Zou J, Cardello C, Cillo AR, Uddin MR, Sagan A, Joy M, Osmanbeyoglu HU, Pogue-Geile KL, McAuliffe PF, Lucas PC, Tseng GC, Lee AV, Bruno TC, Oesterreich S, Vignali DAA. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nat Cancer. 2023;4(4):516-534. PMCID: PMC11194444.
PubMed PMID: 36927792
Journal: Nat Rev Cancer
Publication Date: 2023-03-01
DOI: 10.1038/s41568-022-00531-9
NIH Citation: Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer. 2023;23(3):173-188. PMCID: PMC9992112.
PubMed PMID: 36456755
Journal: Clin Cancer Res
Publication Date: 2023-03-01
DOI: 10.1158/1078-0432.CCR-22-3312
NIH Citation: Karapetyan L, Luke JJ. Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy. Clin Cancer Res. 2023;29(5):835-837. PMCID: PMC9992241.
PubMed PMID: 36534010
Journal: J Immunother Cancer
Publication Date: 2023-03-01
DOI: 10.1136/jitc-2022-006522
NIH Citation: Lontos K, Wang Y, Joshi SK, Frisch AT, Watson MJ, Kumar A, Menk AV, Wang Y, Cumberland R, Lohmueller J, Carrizosa E, Boyerinas B, Delgoffe GM. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. J Immunother Cancer. 2023;11(3). PMCID: PMC10016249.
PubMed PMID: 36914208
Journal: Clin Cancer Res
Publication Date: 2023-02-01
DOI: 10.1158/1078-0432.CCR-22-2355
NIH Citation: Ge H, Ferris RL, Wang JH. Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes. Clin Cancer Res. 2023;29(3):647-658. PMCID: PMC9898159.
PubMed PMID: 36315045
Journal: Nat Immunol
Publication Date: 2023-02-01
DOI: 10.1038/s41590-022-01379-9
NIH Citation: Vignali PDA, DePeaux K, Watson MJ, Ye C, Ford BR, Lontos K, McGaa NK, Scharping NE, Menk AV, Robson SC, Poholek AC, Rivadeneira DB, Delgoffe GM. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nat Immunol. 2023;24(2):267-279. PMCID: PMC10402660.
PubMed PMID: 36543958
Journal: Cancer Treat Rev
Publication Date: 2023-02-01
DOI: 10.1016/j.ctrv.2022.102492
NIH Citation: Ferris RL, Harrington K, Schoenfeld JD, Tahara M, Esdar C, Salmio S, Schroeder A, Bourhis J. Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Treat Rev. 2023;113:102492. PMCID: PMC11227656.
PubMed PMID: 36640618
Journal: Clin Cancer Res
Publication Date: 2023-02-01
DOI: 10.1158/1078-0432.CCR-22-3022
NIH Citation: Augustin RC, Bao R, Luke JJ. Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones. Clin Cancer Res. 2023;29(3):505-507. PMCID: PMC9898080.
PubMed PMID: 36383142
Journal: J Immunother Cancer
Publication Date: 2023-02-01
DOI: 10.1136/jitc-2022-006007
NIH Citation: Augustin RC, Bao R, Luke JJ. Targeting Cbl-b in cancer immunotherapy. J Immunother Cancer. 2023;11(2). PMCID: PMC9906388.
PubMed PMID: 36750253
Journal: J Immunother Cancer
Publication Date: 2023-01-30
DOI: 10.1136/jitc-2023-006761
NIH Citation: Whiteside T, Zarour HM. In memoriam: Soldano Ferrone, MD, PhD (1940-2023). J Immunother Cancer. 2023;11(1). PMCID: PMC9887713.
PubMed PMID: 36717185
Journal: J Clin Oncol
Publication Date: 2023-01-20
DOI: 10.1200/JCO.22.01770
NIH Citation: Augustin RC, Luke JJ. Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma. J Clin Oncol. 2023;41(3):443-446. PMCID: PMC9870232.
PubMed PMID: 36162010
Journal: J Clin Oncol
Publication Date: 2023-01-20
DOI: 10.1200/JCO.22.02264
NIH Citation: Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 2023;41(3):425-435.
PubMed PMID: 36649675
Journal: J Clin Oncol
Publication Date: 2023-01-10
DOI: 10.1200/JCO.22.01763
NIH Citation: Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186-197. PMCID: PMC9839305.
PubMed PMID: 36166727
Journal: Cell Metab
Publication Date: 2022-12-06
DOI: 10.1016/j.cmet.2022.11.010
NIH Citation: Zarour HM. Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade. Cell Metab. 2022;34(12):1903-1905.
PubMed PMID: 36476933
Journal: Clin Cancer Res
Publication Date: 2022-12-01
DOI: 10.1158/1078-0432.CCR-21-2390
NIH Citation: Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022;28(23):5030-5039. PMCID: PMC9669281.
PubMed PMID: 35579997
Journal: J Extracell Vesicles
Publication Date: 2022-12-01
DOI: 10.1002/jev2.12294
NIH Citation: Ludwig N, Yerneni SS, Azambuja JH, Pietrowska M, Widłak P, Hinck CS, Głuszko A, Szczepański MJ, Kärmer T, Kallinger I, Schulz D, Bauer RJ, Spanier G, Spoerl S, Meier JK, Ettl T, Razzo BM, Reichert TE, Hinck AP, Whiteside TL. TGFβ(+) small extracellular vesicles from head and neck squamous cell carcinoma cells reprogram macrophages towards a pro-angiogenic phenotype. J Extracell Vesicles. 2022;11(12):e12294. PMCID: PMC9764108.
PubMed PMID: 36537293
Journal: Clin Cancer Res
Publication Date: 2022-11-14
DOI: 10.1158/1078-0432.CCR-22-2277
NIH Citation: Anagnostou V, Luke JJ. Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade. Clin Cancer Res. 2022;28(22):4835-4837. PMCID: PMC9669208.
PubMed PMID: 36103258
Journal: JAMA Oncol
Publication Date: 2022-11-01
DOI: 10.1001/jamaoncol.2022.3776
NIH Citation: Puthanmadhom Narayanan S, Najjar YG. Hereditary Cancer Syndromes-A Broader Clinical Spectrum Than Previously Understood? JAMA Oncol. 2022;8(11):1698-1699.
PubMed PMID: 36048458
Journal: Semin Cancer Biol
Publication Date: 2022-11-01
DOI: 10.1016/j.semcancer.2022.05.002
NIH Citation: Sun R, Gao DS, Shoush J, Lu B. The IL-1 family in tumorigenesis and antitumor immunity. Semin Cancer Biol. 2022;86(Pt 2):280-295.
PubMed PMID: 35580824
Journal: Trends Cancer
Publication Date: 2022-11-01
DOI: 10.1016/j.trecan.2022.06.008
NIH Citation: Shan F, Somasundaram A, Bruno TC, Workman CJ, Vignali DAA. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer. 2022;8(11):944-961. PMCID: PMC9588644.
PubMed PMID: 35853825
Journal: Clin Cancer Res
Publication Date: 2022-10-14
DOI: 10.1158/1078-0432.CCR-21-1129
NIH Citation: Davar D, Zarour HM. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. Clin Cancer Res. 2022;28(20):4370-4384. PMCID: PMC9561605.
PubMed PMID: 35748749
Journal: J Am Acad Dermatol
Publication Date: 2022-10-01
DOI: 10.1016/j.jaad.2022.05.008
NIH Citation: Shaikh SS, Yang X, Fortman DD, Wang H, Davar D, Luke JJ, Zarour H, Kirkwood JM, Najjar YG. A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma. J Am Acad Dermatol. 2022;87(4):906-908. PMCID: PMC9085439.
PubMed PMID: 35551967
Journal: Clin Cancer Res
Publication Date: 2022-09-15
DOI: 10.1158/1078-0432.CCR-22-1664
NIH Citation: Hassel JC, Luke JJ. Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy. Clin Cancer Res. 2022;28(18):3914-3916. PMCID: PMC9494631.
PubMed PMID: 36106401
Journal: Clin Cancer Res
Publication Date: 2022-09-15
DOI: 10.1158/1078-0432.CCR-22-0339
NIH Citation: Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, Holland A, Wong P, Sifferlen L, Piper D, Sirard CA, Merghoub T, Wolchok JD, Luke JJ. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022;28(18):3990-4002. PMCID: PMC9475244.
PubMed PMID: 35499569
Journal: Lancet
Publication Date: 2022-08-20
DOI: 10.1016/S0140-6736(22)01350-2
NIH Citation: Luke JJ, Ibrahim N, Eggermont AM. Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply. Lancet. 2022;400(10352):559-560.
PubMed PMID: 35988561
Journal: Sci Immunol
Publication Date: 2022-08-05
DOI: 10.1126/sciimmunol.abj9123
NIH Citation: Ford BR, Vignali PDA, Rittenhouse NL, Scharping NE, Peralta R, Lontos K, Frisch AT, Delgoffe GM, Poholek AC. Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. Sci Immunol. 2022;7(74):eabj9123. PMCID: PMC9851604.
PubMed PMID: 35930654
Journal: J Immunother Cancer
Publication Date: 2022-08-01
DOI: 10.1136/jitc-2022-005036
NIH Citation: Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, Wright J, Forde PM, Ferris RL. Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer. 2022;10(8). PMCID: PMC9386211.
PubMed PMID: 35973745
Journal: Nat Rev Clin Oncol
Publication Date: 2022-07-01
DOI: 10.1038/s41571-022-00630-4
NIH Citation: Eggermont AMM, Hamid O, Long GV, Luke JJ. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol. 2022;19(7):431-439. PMCID: PMC11075933.
PubMed PMID: 35468949
Journal: J Clin Invest
Publication Date: 2022-06-15
DOI: 10.1172/JCI161052
NIH Citation: Filderman JN, Storkus WJ. Finding the right help in the tumor microenvironment. J Clin Invest. 2022;132(12). PMCID: PMC9197508.
PubMed PMID: 35703176
Journal: Nat Immunol
Publication Date: 2022-06-01
DOI: 10.1038/s41590-022-01210-5
NIH Citation: Grebinoski S, Zhang Q, Cillo AR, Manne S, Xiao H, Brunazzi EA, Tabib T, Cardello C, Lian CG, Murphy GF, Lafyatis R, Wherry EJ, Das J, Workman CJ, Vignali DAA. Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat Immunol. 2022;23(6):868-877. PMCID: PMC9179227.
PubMed PMID: 35618829
Journal: Clin Cancer Res
Publication Date: 2022-05-13
DOI: 10.1158/1078-0432.CCR-21-3659
NIH Citation: Orr B, Mahdi H, Fang Y, Strange M, Uygun I, Rana M, Zhang L, Suarez Mora A, Pusateri A, Elishaev E, Kang C, Tseng G, Gooding W, Edwards RP, Kalinski P, Vlad AM. Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity. Clin Cancer Res. 2022;28(10):2038-2049. PMCID: PMC9106847.
PubMed PMID: 35046055
Journal: J Clin Invest
Publication Date: 2022-05-02
DOI: 10.1172/JCI159473
NIH Citation: Shurin MR, Umansky V. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy. J Clin Invest. 2022;132(9). PMCID: PMC9057611.
PubMed PMID: 35499071
Journal: J Clin Invest
Publication Date: 2022-05-02
DOI: 10.1172/JCI152864
NIH Citation: Pagliano O, Morrison RM, Chauvin JM, Banerjee H, Davar D, Ding Q, Tanegashima T, Gao W, Chakka SR, DeBlasio R, Lowin A, Kara K, Ka M, Zidi B, Amin R, Raphael I, Zhang S, Watkins SC, Sander C, Kirkwood JM, Bosenberg M, Anderson AC, Kuchroo VK, Kane LP, Korman AJ, Rajpal A, West SM, Han M, Bee C, Deng X, Schebye XM, Strop P, Zarour HM. Tim-3 mediates T cell trogocytosis to limit antitumor immunity. J Clin Invest. 2022;132(9). PMCID: PMC9057587.
PubMed PMID: 35316223
Journal: Trends Immunol
Publication Date: 2022-05-01
DOI: 10.1016/j.it.2022.03.004
NIH Citation: Nayak DA, Binder RJ. Agents of cancer immunosurveillance: HSPs and dsDNA. Trends Immunol. 2022;43(5):404-413. PMCID: PMC9058224.
PubMed PMID: 35382994
Journal: Nat Immunol
Publication Date: 2022-05-01
DOI: 10.1038/s41590-022-01176-4
NIH Citation: Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, Zhang H, Kriwacki R, Bruchez MP, Watkins SC, Workman CJ, Vignali DAA. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat Immunol. 2022;23(5):757-767. PMCID: PMC9106921.
PubMed PMID: 35437325
Journal: Lancet
Publication Date: 2022-04-30
DOI: 10.1016/S0140-6736(22)00562-1
NIH Citation: Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM, KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718-1729.
PubMed PMID: 35367007
Journal: Clin Cancer Res
Publication Date: 2022-04-01
DOI: 10.1158/1078-0432.CCR-21-0426
NIH Citation: Ferris RL, Moskovitz J, Kunning S, Ruffin AT, Reeder C, Ohr J, Gooding WE, Kim S, Karlovits BJ, Vignali DAA, Duvvuri U, Johnson JT, Petro D, Heron DE, Clump DA, Bruno TC, Bauman JE. Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2022;28(7):1335-1344. PMCID: PMC9164766.
PubMed PMID: 35091445
Journal: Nat Rev Immunol
Publication Date: 2022-03-01
DOI: 10.1038/s41577-021-00566-3
NIH Citation: Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158-172. PMCID: PMC8688586.
PubMed PMID: 34155388
Journal: Clin Cancer Res
Publication Date: 2022-02-15
DOI: 10.1158/1078-0432.CCR-21-1963
NIH Citation: Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Müller T, Nair N, Luke JJ. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022;28(4):677-688.
PubMed PMID: 34716197
Journal: J Immunother Cancer
Publication Date: 2022-02-01
DOI: 10.1136/jitc-2021-004089
NIH Citation: Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022;10(2). PMCID: PMC8830302.
PubMed PMID: 35135866
Journal: J Clin Invest
Publication Date: 2022-01-18
DOI: 10.1172/JCI148549
NIH Citation: Watson MJ, Delgoffe GM. Fighting in a wasteland: deleterious metabolites and antitumor immunity. J Clin Invest. 2022;132(2). PMCID: PMC8759785.
PubMed PMID: 35040434
Journal: J Clin Oncol
Publication Date: 2022-01-10
DOI: 10.1200/JCO.21.01752
NIH Citation: Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022;40(2):138-149. PMCID: PMC8718241.
PubMed PMID: 34699271
Journal: J Immunother Cancer
Publication Date: 2022-01-01
DOI: 10.1136/jitc-2021-004310
NIH Citation: Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022;10(1). PMCID: PMC8788316.
PubMed PMID: 35074904
Journal: Nat Immunol
Publication Date: 2022-01-01
DOI: 10.1038/s41590-021-01078-x
NIH Citation: Weisel NM, Joachim SM, Smita S, Callahan D, Elsner RA, Conter LJ, Chikina M, Farber DL, Weisel FJ, Shlomchik MJ. Surface phenotypes of naive and memory B cells in mouse and human tissues. Nat Immunol. 2022;23(1):135-145. PMCID: PMC8712407.
PubMed PMID: 34937918
Journal: Nat Cancer
Publication Date: 2022-01-01
DOI: 10.1038/s43018-021-00319-0
NIH Citation: Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, Pollack IF. The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer. 2022;3(1):11-24.
PubMed PMID: 35121998
Journal: Nat Commun
Publication Date: 2021-12-17
DOI: 10.1038/s41467-021-27619-4
NIH Citation: Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021;12(1):7338. PMCID: PMC8683505.
PubMed PMID: 34921143
Journal: Immunity
Publication Date: 2021-12-14
DOI: 10.1016/j.immuni.2021.11.003
NIH Citation: Overacre-Delgoffe AE, Bumgarner HJ, Cillo AR, Burr AHP, Tometich JT, Bhattacharjee A, Bruno TC, Vignali DAA, Hand TW. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity. 2021;54(12):2812-2824.e4. PMCID: PMC8865366.
PubMed PMID: 34861182
Journal: Sci Transl Med
Publication Date: 2021-12-08
DOI: 10.1126/scitranslmed.abf8495
NIH Citation: Chuckran CA, Cillo AR, Moskovitz J, Overacre-Delgoffe A, Somasundaram AS, Shan F, Magnon GC, Kunning SR, Abecassis I, Zureikat AH, Luketich J, Pennathur A, Sembrat J, Rojas M, Merrick DT, Taylor SE, Orr B, Modugno F, Buckanovich R, Schoen RE, Kim S, Duvvuri U, Zeh H, Edwards R, Kirkwood JM, Coffman L, Ferris RL, Bruno TC, Vignali DAA. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. Sci Transl Med. 2021;13(623):eabf8495. PMCID: PMC9022491.
PubMed PMID: 34878821
Journal: Nat Rev Immunol
Publication Date: 2021-12-01
DOI: 10.1038/s41577-021-00541-y
NIH Citation: DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021;21(12):785-797. PMCID: PMC8553800.
PubMed PMID: 33927375
Journal: J Immunother Cancer
Publication Date: 2021-11-01
DOI: 10.1136/jitc-2021-003675
NIH Citation: Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, Linch E, Lowman GM, Kalinski P, Butterfield LH, Tarhini A, Tawbi H, Kirkwood JM. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021;9(11). PMCID: PMC8593702.
PubMed PMID: 34782430
Journal: Lancet Haematol
Publication Date: 2021-11-01
DOI: 10.1016/S2352-3026(21)00271-4
NIH Citation: Querfeld C, Thompson JA, Taylor MH, DeSimone JA, Zain JM, Shustov AR, Johns C, McCann S, Lin GHY, Petrova PS, Uger RA, Molloy N, Shou Y, Akilov OE. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. Lancet Haematol. 2021;8(11):e808-e817.
PubMed PMID: 34627593
Journal: Redox Biol
Publication Date: 2021-11-01
DOI: 10.1016/j.redox.2021.102143
NIH Citation: Vats K, Kruglov O, Mizes A, Samovich SN, Amoscato AA, Tyurin VA, Tyurina YY, Kagan VE, Bunimovich YL. Keratinocyte death by ferroptosis initiates skin inflammation after UVB exposure. Redox Biol. 2021;47:102143. PMCID: PMC8487085.
PubMed PMID: 34592565
Journal: Clin Cancer Res
Publication Date: 2021-10-15
DOI: 10.1158/1078-0432.CCR-21-0810
NIH Citation: Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021;27(20):5510-5518.
PubMed PMID: 34168049
Journal: Immunity
Publication Date: 2021-10-12
DOI: 10.1016/j.immuni.2021.08.029
NIH Citation: Andrews LP, Vignali KM, Szymczak-Workman AL, Burton AR, Brunazzi EA, Ngiow SF, Harusato A, Sharpe AH, Wherry EJ, Taniuchi I, Workman CJ, Vignali DAA. A Cre-driven allele-conditioning line to interrogate CD4(+) conventional T cells. Immunity. 2021;54(10):2209-2217.e6.
PubMed PMID: 34551314
Journal: Clin Cancer Res
Publication Date: 2021-10-01
DOI: 10.1158/1078-0432.CCR-21-2406
NIH Citation: Jameson-Lee M, Luke JJ. Ipilimumab Combination Dosing: Less is More. Clin Cancer Res. 2021;27(19):5153-5155. PMCID: PMC8807780.
PubMed PMID: 34341015
Journal: EBioMedicine
Publication Date: 2021-09-01
DOI: 10.1016/j.ebiom.2021.103571
NIH Citation: Foster A, Nigam S, Tatum DS, Raphael I, Xu J, Kumar R, Plakseychuk E, Latoche JD, Vincze S, Li B, Giri R, McCarl LH, Edinger R, Ak M, Peddagangireddy V, Foley LM, Hitchens TK, Colen RR, Pollack IF, Panigrahy A, Magda D, Anderson CJ, Edwards WB, Kohanbash G. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma. EBioMedicine. 2021;71:103571. PMCID: PMC8446777.
PubMed PMID: 34530385
Journal: Ann Intern Med
Publication Date: 2021-09-01
DOI: 10.7326/L21-0441
NIH Citation: Yang X, Karapetyan L, Kirkwood JM. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Ann Intern Med. 2021;174(9):1345.
PubMed PMID: 34543597
Journal: J Clin Oncol
Publication Date: 2021-08-20
DOI: 10.1200/JCO.21.00079
NIH Citation: Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021;39(24):2647-2655. PMCID: PMC8376314.
PubMed PMID: 33945288
Journal: J Am Chem Soc
Publication Date: 2021-08-11
DOI: 10.1021/jacs.1c03815
NIH Citation: Sappa S, Dey D, Sudhamalla B, Islam K. Catalytic Space Engineering as a Strategy to Activate C-H Oxidation on 5-Methylcytosine in Mammalian Genome. J Am Chem Soc. 2021;143(31):11891-11896. PMCID: PMC9153246.
PubMed PMID: 34323479
Journal: Clin Cancer Res
Publication Date: 2021-08-01
DOI: 10.1158/1078-0432.CCR-20-4301
NIH Citation: Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux J, Summit IB, Bender JO, Kim JY, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021;27(15):4195-4204. PMCID: PMC8338751.
PubMed PMID: 33753453
Journal: J Immunother Cancer
Publication Date: 2021-08-01
DOI: 10.1136/jitc-2021-002597
NIH Citation: Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021;9(8). PMCID: PMC8365813.
PubMed PMID: 34389617
Journal: Nat Methods
Publication Date: 2021-08-01
DOI: 10.1038/s41592-020-0867-z
NIH Citation: Joglekar AV, Li G. T cell antigen discovery. Nat Methods. 2021;18(8):873-880.
PubMed PMID: 32632239
Journal: Cell
Publication Date: 2021-07-22
DOI: 10.1016/j.cell.2021.06.015
NIH Citation: Brown CC, Gottschalk RA. Volume control: Turning the dial on regulatory T cells. Cell. 2021;184(15):3847-3849.
PubMed PMID: 34297928
Journal: Sci Transl Med
Publication Date: 2021-07-14
DOI: 10.1126/scitranslmed.abb3631
NIH Citation: Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, Engle JW, Le T, Kim K, Bednarz B, Sondel PM, Weichert J, Morris ZS. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021;13(602). PMCID: PMC8449934.
PubMed PMID: 34261797
Journal: J Immunother Cancer
Publication Date: 2021-07-01
DOI: 10.1136/jitc-2021-002820
NIH Citation: Najjar YG. Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver? J Immunother Cancer. 2021;9(7). PMCID: PMC8314703.
PubMed PMID: 34312244
Journal: Nat Commun
Publication Date: 2021-06-07
DOI: 10.1038/s41467-021-23355-x
NIH Citation: Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, Lampenfeld C, Atiya HI, Abecassis I, Kürten CHL, Qi Z, Soose R, Duvvuri U, Kim S, Oesterrich S, Lafyatis R, Coffman LG, Ferris RL, Vignali DAA, Bruno TC. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun. 2021;12(1):3349. PMCID: PMC8184766.
PubMed PMID: 34099645
Journal: J Immunother Cancer
Publication Date: 2021-06-01
DOI: 10.1136/jitc-2021-002568
NIH Citation: Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021;9(6). PMCID: PMC8183204.
PubMed PMID: 34083421
Journal: Immunity
Publication Date: 2021-05-11
DOI: 10.1016/j.immuni.2021.04.018
NIH Citation: Cheemalavagu N, Gottschalk RA. Time will tell: The temporal code of immune threats. Immunity. 2021;54(5):845-847.
PubMed PMID: 33979580
Journal: J Clin Oncol
Publication Date: 2021-05-10
DOI: 10.1200/JCO.21.00027
NIH Citation: Lai SY, Ferris RL. Reply to N. Hirshoren et al and D. Chakrabarti et al. J Clin Oncol. 2021;39(14):1600-1601.
PubMed PMID: 33705206
Journal: J Immunother Cancer
Publication Date: 2021-05-01
DOI: 10.1136/jitc-2021-002535
NIH Citation: Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021;9(5). PMCID: PMC8108687.
PubMed PMID: 33963015
Journal: J Immunother Cancer
Publication Date: 2021-05-01
DOI: 10.1136/jitc-2020-002088
NIH Citation: Zandberg DP, Menk AV, Velez M, Normolle D, DePeaux K, Liu A, Ferris RL, Delgoffe GM. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. J Immunother Cancer. 2021;9(5). PMCID: PMC8126285.
PubMed PMID: 33986123
Journal: Nature
Publication Date: 2021-03-01
DOI: 10.1038/s41586-020-03045-2
NIH Citation: Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, Menk AV, Rittenhouse NL, DePeaux K, Whetstone RD, Vignali DAA, Hand TW, Poholek AC, Morrison BM, Rothstein JD, Wendell SG, Delgoffe GM. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591(7851):645-651. PMCID: PMC7990682.
PubMed PMID: 33589820
Journal: Science
Publication Date: 2021-02-05
DOI: 10.1126/science.abf3363
NIH Citation: Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, Zidi B, Zhang S, Badger JH, Vetizou M, Cole AM, Fernandes MR, Prescott S, Costa RGF, Balaji AK, Morgun A, Vujkovic-Cvijin I, Wang H, Borhani AA, Schwartz MB, Dubner HM, Ernst SJ, Rose A, Najjar YG, Belkaid Y, Kirkwood JM, Trinchieri G, Zarour HM. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595-602. PMCID: PMC8097968.
PubMed PMID: 33542131
Journal: Nat Immunol
Publication Date: 2021-02-01
DOI: 10.1038/s41590-020-00834-9
NIH Citation: Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Peralta R, Wang Y, Wang Y, DePeaux K, Poholek AC, Delgoffe GM. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22(2):205-215. PMCID: PMC7971090.
PubMed PMID: 33398183
Journal: J Immunother Cancer
Publication Date: 2021-02-01
DOI: 10.1136/jitc-2020-002015
NIH Citation: Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021;9(2). PMCID: PMC7898862.
PubMed PMID: 33608377
Journal: J Extracell Vesicles
Publication Date: 2021-02-01
DOI: 10.1002/jev2.12063
NIH Citation: Pietrowska M, Zebrowska A, Gawin M, Marczak L, Sharma P, Mondal S, Mika J, Polańska J, Ferrone S, Kirkwood JM, Widlak P, Whiteside TL. Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. J Extracell Vesicles. 2021;10(4):e12063. PMCID: PMC7876545.
PubMed PMID: 33613873
Journal: J Immunother Cancer
Publication Date: 2021-02-01
DOI: 10.1136/jitc-2020-001906
NIH Citation: Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer. 2021;9(2). PMCID: PMC7852948.
PubMed PMID: 33526609
Journal: Trends Immunol
Publication Date: 2021-02-01
DOI: 10.1016/j.it.2020.12.005
NIH Citation: McPherson AC, Pandey SP, Bender MJ, Meisel M. Systemic Immunoregulatory Consequences of Gut Commensal Translocation. Trends Immunol. 2021;42(2):137-150. PMCID: PMC10110348.
PubMed PMID: 33422410
Journal: J Exp Med
Publication Date: 2021-01-04
DOI: 10.1084/jem.20192179
NIH Citation: Burke KP, Grebinoski S, Sharpe AH, Vignali DAA. Understanding adverse events of immunotherapy: A mechanistic perspective. J Exp Med. 2021;218(1). PMCID: PMC7754677.
PubMed PMID: 33601411
Journal: Clin Cancer Res
Publication Date: 2020-12-15
DOI: 10.1158/1078-0432.CCR-20-1790
NIH Citation: Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020;26(24):6437-6444. PMCID: PMC8561652.
PubMed PMID: 33028595
Journal: Nat Rev Clin Oncol
Publication Date: 2020-12-01
DOI: 10.1038/s41571-020-00437-1
NIH Citation: Rohatgi A, Kirkwood JM. Cancer vaccine induces potent T cell responses - but is it enough? Nat Rev Clin Oncol. 2020;17(12):721-722.
PubMed PMID: 32978607
Journal: J Clin Oncol
Publication Date: 2020-12-01
DOI: 10.1200/JCO.20.02716
NIH Citation: Lai SY, Ferris RL. Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. J Clin Oncol. 2020;38(34):3983-3986.
PubMed PMID: 33052758
Journal: Nat Rev Clin Oncol
Publication Date: 2020-12-01
DOI: 10.1038/s41571-020-00433-5
NIH Citation: Whiteside TL. Validation of plasma-derived small extracellular vesicles as cancer biomarkers. Nat Rev Clin Oncol. 2020;17(12):719-720.
PubMed PMID: 32943766
Journal: Trends Immunol
Publication Date: 2020-11-01
DOI: 10.1016/j.it.2020.09.005
NIH Citation: Siller M, Zeng Y, Hinterleitner R. Can Microbes Boost Tregs to Suppress Food Sensitivities? Trends Immunol. 2020;41(11):967-971.
PubMed PMID: 33036909
Journal: Genome Med
Publication Date: 2020-10-27
DOI: 10.1186/s13073-020-00787-6
NIH Citation: Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020;12(1):90. PMCID: PMC7590690.
PubMed PMID: 33106165
Journal: Clin Cancer Res
Publication Date: 2020-10-15
DOI: 10.1158/1078-0432.CCR-20-0575
NIH Citation: Chauvin JM, Ka M, Pagliano O, Menna C, Ding Q, DeBlasio R, Sanders C, Hou J, Li XY, Ferrone S, Davar D, Kirkwood JM, Johnston RJ, Korman AJ, Smyth MJ, Zarour HM. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020;26(20):5520-5533. PMCID: PMC8045409.
PubMed PMID: 32591463
Journal: Blood
Publication Date: 2020-10-08
DOI: 10.1182/blood.2019004725
NIH Citation: Gaydosik AM, Queen DS, Trager MH, Akilov OE, Geskin LJ, Fuschiotti P. Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma. Blood. 2020;136(15):1748-1759. PMCID: PMC7544545.
PubMed PMID: 32438399
Journal: Lancet Oncol
Publication Date: 2020-10-01
DOI: 10.1016/S1470-2045(20)30465-4
NIH Citation: Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283-1295.
PubMed PMID: 33002436
Journal: Trends Cancer
Publication Date: 2020-09-01
DOI: 10.1016/j.trecan.2020.05.009
NIH Citation: Subbiah V, Baik C, Kirkwood JM. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020;6(9):797-810.
PubMed PMID: 32540454
Journal: Clin Cancer Res
Publication Date: 2020-09-01
DOI: 10.1158/1078-0432.CCR-20-2127
NIH Citation: Filderman JN, Storkus WJ. Neoepitopes as Difference Makers for General Cancer Vaccines? Clin Cancer Res. 2020;26(17):4429-4431. PMCID: PMC7484287.
PubMed PMID: 32646923
Journal: Nat Immunol
Publication Date: 2020-09-01
DOI: 10.1038/s41590-020-0733-2
NIH Citation: Liu C, Somasundaram A, Manne S, Gocher AM, Szymczak-Workman AL, Vignali KM, Scott EN, Normolle DP, John Wherry E, Lipson EJ, Ferris RL, Bruno TC, Workman CJ, Vignali DAA. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. Nat Immunol. 2020;21(9):1010-1021. PMCID: PMC7442600.
PubMed PMID: 32661362
Journal: J Immunother Cancer
Publication Date: 2020-09-01
DOI: 10.1136/jitc-2020-000957
NIH Citation: Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2). PMCID: PMC7477968.
PubMed PMID: 32900861
Journal: Nat Commun
Publication Date: 2020-08-24
DOI: 10.1038/s41467-020-17991-y
NIH Citation: Zhou M, Sacirbegovic F, Zhao K, Rosenberger S, Shlomchik WD. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect. Nat Commun. 2020;11(1):4227. PMCID: PMC7445289.
PubMed PMID: 32839441
Journal: Clin Cancer Res
Publication Date: 2020-08-15
DOI: 10.1158/1078-0432.CCR-20-1558
NIH Citation: Shoushtari AN, Bao R, Luke JJ. PD-1 Blockade in Chinese versus Western Patients with Melanoma. Clin Cancer Res. 2020;26(16):4171-4173. PMCID: PMC7442612.
PubMed PMID: 32487680
Journal: J Extracell Vesicles
Publication Date: 2020-08-07
DOI: 10.1080/20013078.2020.1800979
NIH Citation: Hong CS, Jeong E, Boyiadzis M, Whiteside TL. Increased small extracellular vesicle secretion after chemotherapy via upregulation of cholesterol metabolism in acute myeloid leukaemia. J Extracell Vesicles. 2020;9(1):1800979. PMCID: PMC7480590.
PubMed PMID: 32944189
Journal: Clin Cancer Res
Publication Date: 2020-08-01
DOI: 10.1158/1078-0432.CCR-19-1321
NIH Citation: Garris CS, Luke JJ. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. Clin Cancer Res. 2020;26(15):3901-3907. PMCID: PMC7607412.
PubMed PMID: 32332013
Journal: Sci Immunol
Publication Date: 2020-07-17
DOI: 10.1126/sciimmunol.abc2728
NIH Citation: Andrews LP, Somasundaram A, Moskovitz JM, Szymczak-Workman AL, Liu C, Cillo AR, Lin H, Normolle DP, Moynihan KD, Taniuchi I, Irvine DJ, Kirkwood JM, Lipson EJ, Ferris RL, Bruno TC, Workman CJ, Vignali DAA. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020;5(49). PMCID: PMC7901539.
PubMed PMID: 32680952
Journal: Clin Cancer Res
Publication Date: 2020-07-01
DOI: 10.1158/1078-0432.CCR-19-4042
NIH Citation: Zeh HJ, Bahary N, Boone BA, Singhi AD, Miller-Ocuin JL, Normolle DP, Zureikat AH, Hogg ME, Bartlett DL, Lee KK, Tsung A, Marsh JW, Murthy P, Tang D, Seiser N, Amaravadi RK, Espina V, Liotta L, Lotze MT. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clin Cancer Res. 2020;26(13):3126-3134. PMCID: PMC8086597.
PubMed PMID: 32156749
Journal: J Immunother Cancer
Publication Date: 2020-07-01
DOI: 10.1136/jitc-2020-001020
NIH Citation: Bao R, Hernandez K, Huang L, Luke JJ. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer. 2020;8(2). PMCID: PMC7372174.
PubMed PMID: 32675312
Journal: J Immunother Cancer
Publication Date: 2020-07-01
DOI: 10.1136/jitc-2020-000967
NIH Citation: Chuckran CA, Liu C, Bruno TC, Workman CJ, Vignali DA. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. J Immunother Cancer. 2020;8(2). PMCID: PMC7368550.
PubMed PMID: 32675311
Journal: J Clin Invest
Publication Date: 2020-06-01
DOI: 10.1172/JCI132328
NIH Citation: Tilstra JS, John S, Gordon RA, Leibler C, Kashgarian M, Bastacky S, Nickerson KM, Shlomchik MJ. B cell-intrinsic TLR9 expression is protective in murine lupus. J Clin Invest. 2020;130(6):3172-3187. PMCID: PMC7260024.
PubMed PMID: 32191633
Journal: Drugs
Publication Date: 2020-06-01
DOI: 10.1007/s40265-020-01320-0
NIH Citation: Somasundaram A, Socinski MA, Villaruz LC. Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs. 2020;80(9):883-892. PMCID: PMC8579493.
PubMed PMID: 32436070
Journal: J Immunother Cancer
Publication Date: 2020-06-01
DOI: 10.1136/jitc-2019-000331
NIH Citation: Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, Chowdhary A, Chandra S, Kennedy J, Puzanov I, Ernstoff M, Vachhani P, Drabick J, Singh A, Xu T, Yang J, Carvajal R, Manson D, Kirkwood JM, Cohen J, Sullivan R, Johnson D, Funchain P, Shoushtari A. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020;8(1). PMCID: PMC7319717.
PubMed PMID: 32581057
Journal: Nat Rev Clin Oncol
Publication Date: 2020-04-01
DOI: 10.1038/s41571-020-0328-8
NIH Citation: Luke JJ, Ascierto PA. Biology confirmed but biomarkers elusive in melanoma immunotherapy. Nat Rev Clin Oncol. 2020;17(4):198-199.
PubMed PMID: 31974501
Journal: Cancer Treat Rev
Publication Date: 2020-03-01
DOI: 10.1016/j.ctrv.2019.101947
NIH Citation: Solinas C, Aiello M, Migliori E, Willard-Gallo K, Emens LA. Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. Cancer Treat Rev. 2020;84:101947.
PubMed PMID: 31926403
Journal: Nat Immunol
Publication Date: 2020-03-01
DOI: 10.1038/s41590-020-0598-4
NIH Citation: Weisel FJ, Mullett SJ, Elsner RA, Menk AV, Trivedi N, Luo W, Wikenheiser D, Hawse WF, Chikina M, Smita S, Conter LJ, Joachim SM, Wendell SG, Jurczak MJ, Winkler TH, Delgoffe GM, Shlomchik MJ. Germinal center B cells selectively oxidize fatty acids for energy while conducting minimal glycolysis. Nat Immunol. 2020;21(3):331-342. PMCID: PMC7112716.
PubMed PMID: 32066950
Journal: J Clin Oncol
Publication Date: 2020-02-20
DOI: 10.1200/JCO.19.01381
NIH Citation: Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020;38(6):567-575. PMCID: PMC7030886.
PubMed PMID: 31880964
Journal: Clin Cancer Res
Publication Date: 2020-02-15
DOI: 10.1158/1078-0432.CCR-19-1223
NIH Citation: Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020;26(4):804-811. PMCID: PMC7055933.
PubMed PMID: 31558480
Journal: Immunity
Publication Date: 2020-01-14
DOI: 10.1016/j.immuni.2019.11.014
NIH Citation: Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity. 2020;52(1):183-199.e9. PMCID: PMC7201194.
PubMed PMID: 31924475
Journal: J Control Release
Publication Date: 2020-01-10
DOI: 10.1016/j.jconrel.2019.11.023
NIH Citation: Balmert SC, Carey CD, Falo GD, Sethi SK, Erdos G, Korkmaz E, Falo LD Jr. Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination. J Control Release. 2020;317:336-346. PMCID: PMC8237702.
PubMed PMID: 31756393
Journal: Immunity
Publication Date: 2019-12-17
DOI: 10.1016/j.immuni.2019.10.004
NIH Citation: Trivedi N, Weisel F, Smita S, Joachim S, Kader M, Radhakrishnan A, Clouser C, Rosenfeld AM, Chikina M, Vigneault F, Hershberg U, Ismail N, Shlomchik MJ. Liver Is a Generative Site for the B Cell Response to Ehrlichia muris. Immunity. 2019;51(6):1088-1101.e5. PMCID: PMC6955021.
PubMed PMID: 31732168
Journal: Lancet
Publication Date: 2019-11-23
DOI: 10.1016/S0140-6736(19)32539-5
NIH Citation: Ferris RL, Licitra L. PD-1 immunotherapy for recurrent or metastatic HNSCC. Lancet. 2019;394(10212):1882-1884.
PubMed PMID: 31679948
Journal: Nat Immunol
Publication Date: 2019-11-01
DOI: 10.1038/s41590-019-0512-0
NIH Citation: Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425-1434.
PubMed PMID: 31611702
Journal: J Immunother Cancer
Publication Date: 2019-10-23
DOI: 10.1186/s40425-019-0740-8
NIH Citation: Molinero L, Li Y, Chang CW, Maund S, Berg M, Harrison J, Fassò M, O'Hear C, Hegde P, Emens LA. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019;7(1):274. PMCID: PMC6813065.
PubMed PMID: 31647026
Journal: J Am Chem Soc
Publication Date: 2019-10-02
DOI: 10.1021/jacs.9b05725
NIH Citation: Arora S, Horne WS, Islam K. Engineering Methyllysine Writers and Readers for Allele-Specific Regulation of Protein-Protein Interactions. J Am Chem Soc. 2019;141(39):15466-15470. PMCID: PMC6988089.
PubMed PMID: 31518125
Journal: Immunity
Publication Date: 2019-09-17
DOI: 10.1016/j.immuni.2019.07.003
NIH Citation: Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R, Ferris RL, Sarkar SN, Thorne SH, Delgoffe GM. Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity. 2019;51(3):548-560.e4. PMCID: PMC6903394.
PubMed PMID: 31471106
Journal: Clin Cancer Res
Publication Date: 2019-09-01
DOI: 10.1158/1078-0432.CCR-18-3944
NIH Citation: Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019;25(17):5221-5230. PMCID: PMC7721346.
PubMed PMID: 31239321
Journal: Immunity
Publication Date: 2019-08-20
DOI: 10.1016/j.immuni.2019.06.017
NIH Citation: Liu C, Chikina M, Deshpande R, Menk AV, Wang T, Tabib T, Brunazzi EA, Vignali KM, Sun M, Stolz DB, Lafyatis RA, Chen W, Delgoffe GM, Workman CJ, Wendell SG, Vignali DAA. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8(+) T Cell-Derived Interferon-γ. Immunity. 2019;51(2):381-397.e6. PMCID: PMC6703933.
PubMed PMID: 31350177
Journal: J Clin Oncol
Publication Date: 2019-07-10
DOI: 10.1200/JCO.19.00544
NIH Citation: Ferris RL, Cramer JD, Branstetter Iv BF. Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2019;37(20):1683-1685. PMCID: PMC6638595.
PubMed PMID: 31150317
Journal: Nat Med
Publication Date: 2019-07-01
DOI: 10.1038/s41591-019-0480-9
NIH Citation: Gopalakrishna KP, Macadangdang BR, Rogers MB, Tometich JT, Firek BA, Baker R, Ji J, Burr AHP, Ma C, Good M, Morowitz MJ, Hand TW. Maternal IgA protects against the development of necrotizing enterocolitis in preterm infants. Nat Med. 2019;25(7):1110-1115. PMCID: PMC7424541.
PubMed PMID: 31209335
Journal: JAMA Oncol
Publication Date: 2019-07-01
DOI: 10.1001/jamaoncol.2019.0413
NIH Citation: Davar D, Kirkwood JM. PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncol. 2019;5(7):942-943.
PubMed PMID: 31021377
Journal: Nat Immunol
Publication Date: 2019-06-01
DOI: 10.1038/s41590-019-0346-9
NIH Citation: Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20(6):724-735. PMCID: PMC6531353.
PubMed PMID: 30936494
Journal: Nat Immunol
Publication Date: 2019-06-01
DOI: 10.1038/s41590-019-0376-3
NIH Citation: Luo W, Hawse W, Conter L, Trivedi N, Weisel F, Wikenheiser D, Cattley RT, Shlomchik MJ. The AKT kinase signaling network is rewired by PTEN to control proximal BCR signaling in germinal center B cells. Nat Immunol. 2019;20(6):736-746. PMCID: PMC6724213.
PubMed PMID: 31011187
Journal: Cancer Res
Publication Date: 2019-05-15
DOI: 10.1158/0008-5472.CAN-18-3872
NIH Citation: Shurin GV, Kruglov O, Ding F, Lin Y, Hao X, Keskinov AA, You Z, Lokshin AE, LaFramboise WA, Falo LD Jr, Shurin MR, Bunimovich YL. Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth. Cancer Res. 2019;79(10):2736-2747. PMCID: PMC6522315.
PubMed PMID: 30914431
Journal: J Immunother Cancer
Publication Date: 2019-04-24
DOI: 10.1186/s40425-019-0552-x
NIH Citation: Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. J Immunother Cancer. 2019;7(1):113. PMCID: PMC6480917.
PubMed PMID: 31014399
Journal: J Immunother Cancer
Publication Date: 2019-04-18
DOI: 10.1186/s40425-019-0590-4
NIH Citation: Donnenberg AD, Luketich JD, Dhupar R, Donnenberg VS. Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer. 2019;7(1):110. PMCID: PMC6472034.
PubMed PMID: 30999958
Journal: N Engl J Med
Publication Date: 2019-03-07
DOI: 10.1056/NEJMc1900150
NIH Citation: Schmid P, Chui SY, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply. N Engl J Med. 2019;380(10):987-988.
PubMed PMID: 30855757
Journal: Clin Cancer Res
Publication Date: 2019-01-15
DOI: 10.1158/1078-0432.CCR-18-2258
NIH Citation: Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clin Cancer Res. 2019;25(2):524-532. PMCID: PMC6335150.
PubMed PMID: 30420448
Journal: JAMA Oncol
Publication Date: 2019-01-01
DOI: 10.1001/jamaoncol.2018.4224
NIH Citation: Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019;5(1):74-82. PMCID: PMC6439773.
PubMed PMID: 30242306
Journal: J Immunother Cancer
Publication Date: 2018-12-04
DOI: 10.1186/s40425-018-0453-4
NIH Citation: Butterfield LH, Disis ML, Fox BA, Kaufman DR, Khleif SN, Wang E, Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art. J Immunother Cancer. 2018;6(1):138. PMCID: PMC6278162.
PubMed PMID: 30514399
Journal: J Exp Med
Publication Date: 2018-12-03
DOI: 10.1084/jem.20172018
NIH Citation: Uche UU, Piccirillo AR, Kataoka S, Grebinoski SJ, D'Cruz LM, Kane LP. PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt. J Exp Med. 2018;215(12):3165-3179. PMCID: PMC6279406.
PubMed PMID: 30429249
Journal: Gastroenterology
Publication Date: 2018-12-01
DOI: 10.1053/j.gastro.2018.11.008
NIH Citation: Santos PM, Butterfield LH. Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology. 2018;155(6):1684-1686.
PubMed PMID: 30419214
